Significant milestone re Thermo Fisher agreement

Verici Dx PLC

01 July 2024

 

Verici Dx plc

("Verici Dx" or the "Company") 

Achievement of significant milestone under Thermo Fisher Scientific agreement

Successful transfer of pre-transplant prognostic testing technology

Verici Dx plc (AIM: VRCI), a developer of advanced clinical diagnostics for organ transplant, notes that Thermo Fisher Scientific has confirmed the completion of the transfer and achievement of all transfer-related activities for the pre-transplant prognostic testing technology licensed by the Company to Thermo Fisher Scientific under the terms of a global licensing and commercialisation agreement announced on 15 November 2023 (the "Agreement")¹.

This enables Thermo Fisher Scientific to use the technology to develop a LDT ("Laboratory Developed Test") in its own labs. This event triggers a further milestone payment under the Agreement, in line with previously disclosed expectations.

Commenting on the milestone, Sara Barrington, CEO of Verici Dx, said:

"I am delighted to announce this smooth transition between Verici Dx and Thermo Fisher Scientific. This collaboration brings together Verici Dx's innovative technology into Thermo Fisher's new CLIA laboratory in the U.S., which will ultimately benefit patients and the field of organ transplantation."

This announcement contains inside information for the purposes of Article 7 of the UK Market Abuse Regulation (UK MAR). Upon the publication of this announcement, this inside information is now considered to be in the public domain.

Enquiries:

Verici Dx	www.vericidx.com
Sara Barrington, CEO	[e-mail]
Julian Baines, Chairman
Singer Capital Markets (Nominated Adviser & Broker)	Tel: [phone]
Aubrey Powell / Sam Butcher

Notes

1.     Please refer to RNS number 4652T for further information. A copy of this announcement can also be found on the company website https://verici-dx-plc.flint-platform.com/regulatory-news/62760

About Verici Dx plc www.vericidx.com

Verici Dx is a developer of a complementary suite of leading-edge tests forming a kidney transplant platform for personalised patient and organ response risk to assist clinicians in medical management for improved patient outcomes. The underlying technology is based upon artificial intelligence assisted transcriptomic analysis to provide RNA signatures focused upon the immune response and other biological pathway signals critical for transplant prognosis of risk of injury, rejection and graft failure from pre-transplant to late stage. The Company also has a mission to accelerate the pace of innovation by research using the fully characterised data from the underlying technology, including through collaboration with medical device, biopharmaceutical and data science partners.

The foundational research was driven by a deep understanding of cell-mediated immunity and is enabled by access to expertly curated collaborative studies in highly informative cohorts in kidney transplant.

 

END